Efficacy of combined COVID-19 convalescent plasma with oral RNA-dependent RNA polymerase inhibitor treatment versus neutralizing monoclonal antibody therapy …
T Siripongboonsitti, N Nontawong… - Microbiology …, 2023 - Am Soc Microbiol
The effectiveness of neutralizing monoclonal antibodies against emerging variants with
spike protein mutations has been limited. Early high-titer convalescent plasma therapy …
spike protein mutations has been limited. Early high-titer convalescent plasma therapy …
Neutralizing COVID-19 convalescent plasma in adults hospitalized with COVID-19: a blinded, randomized, placebo-controlled trial
WH Self, AP Wheeler, TG Stewart, H Schrager… - Chest, 2022 - Elsevier
Background Convalescent plasma has been one of the most common treatments for COVID-
19, but most clinical trial data to date have not supported its efficacy. Research Question Is …
19, but most clinical trial data to date have not supported its efficacy. Research Question Is …
Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial
CONCOR-1 Study Group… - medRxiv, 2021 - medrxiv.org
The efficacy of convalescent plasma for COVID-19 is unclear. While most randomized
controlled trials have shown negative results, uncontrolled studies have suggested that the …
controlled trials have shown negative results, uncontrolled studies have suggested that the …
Outcomes of convalescent plasma with defined high versus lower neutralizing antibody titers against SARS-CoV-2 among hospitalized patients: CoronaVirus …
LA Bartelt, AJ Markmann, B Nelson, J Keys, H Root… - MBio, 2022 - Am Soc Microbiol
ABSTRACT COVID-19 convalescent plasma (CCP) was an early and widely adopted
putative therapy for severe COVID-19. Results from randomized control trials and …
putative therapy for severe COVID-19. Results from randomized control trials and …
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group, PW Horby… - MedRxiv, 2021 - medrxiv.org
Background Treatment of COVID-19 patients with plasma containing anti-SARS-CoV-2
antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the …
antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the …
Guidance on the use of convalescent plasma to treat immunocompromised patients with coronavirus disease 2019
Abstract Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and
effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a …
effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a …
Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis
Purpose To assess and compare the relative efficacy and safety of anti-SARS-CoV-2
antibody regimens for COVID-19. Methods This systematic review and random-effects …
antibody regimens for COVID-19. Methods This systematic review and random-effects …
Impact of convalescent plasma therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody profile in coronavirus disease 2019 (COVID-19) …
J Tang, G Grubbs, Y Lee, H Golding… - Clinical Infectious …, 2022 - academic.oup.com
Convalescent plasma (CP) have been used for treatment of coronavirus disease 2019
(COVID-19), but their effectiveness varies significantly. Moreover, the impact of CP treatment …
(COVID-19), but their effectiveness varies significantly. Moreover, the impact of CP treatment …
The efficiency of convalescent plasma therapy in the management of critically ill patients infected with COVID-19: a matched cohort study
C Pan, H Chen, J Xie, Y Huang, Y Yang, B Du… - Frontiers in …, 2022 - frontiersin.org
Background The convalescent plasma of patients who recover from coronavirus disease
2019 (COVID-19) contains high titers of neutralizing antibodies, which has potential effects …
2019 (COVID-19) contains high titers of neutralizing antibodies, which has potential effects …
COVID-19 convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency: a randomized trial
K Lacombe, T Hueso, R Porcher, A Mekinian… - MedRxiv, 2022 - medrxiv.org
Objectives Efficacy of convalescent plasma in COVID-19 pneumonia (CPP) is uncertain,
especially in immunocompromised patients. CORIMUNO-CORIPLASM is an open-label …
especially in immunocompromised patients. CORIMUNO-CORIPLASM is an open-label …